Get the Stockscreener App
6.69
0.90%
0.06
After Hours:
6.63
-0.06
-0.90%
Avalo Therapeutics Inc stock is traded at $6.69, with a volume of 112.66K.
It is up +0.90% in the last 24 hours and up +39.67% over the past month.
Avalo Therapeutics Inc is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The company's asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).
See More
Previous Close:
$6.63
Open:
$6.7
24h Volume:
112.66K
Relative Volume:
1.22
Market Cap:
$72.44M
Revenue:
$1.93M
Net Income/Loss:
$-7.96M
P/E Ratio:
-0.00189
EPS:
-3530.8178
Net Cash Flow:
$-36.78M
1W Performance:
+7.04%
1M Performance:
+39.67%
6M Performance:
-11.27%
1Y Performance:
-42.53%
1-Day Range:
$6.3551
$6.75
1-Week Range:
$6.345
$7.15
52-Week Range:
$3.39
$16.00
Avalo Therapeutics Inc Stock (AVTX) Company Profile
Name
Avalo Therapeutics Inc
Sector
Industry
Phone
410-522-8707
Address
1500 LIBERTY RIDGE DRIVE, WAYNE
Compare AVTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AVTX
Avalo Therapeutics Inc
|
6.69 | 71.79M | 1.93M | -7.96M | -36.78M | -3,530.82 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.65 | 121.28B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.10 | 60.96B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
328.81 | 42.77B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
591.99 | 36.21B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
291.47 | 32.08B | 3.81B | -644.79M | -669.77M | -6.24 |
Avalo Therapeutics Inc Stock (AVTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-02-25 | Resumed | H.C. Wainwright | Buy |
| Mar-25-25 | Initiated | Jefferies | Buy |
| Mar-25-25 | Initiated | Stifel | Buy |
| Feb-28-25 | Initiated | Piper Sandler | Overweight |
| Feb-21-25 | Initiated | Wedbush | Outperform |
| Dec-19-24 | Initiated | BTIG Research | Buy |
| Oct-24-24 | Initiated | H.C. Wainwright | Neutral |
| Apr-16-24 | Upgrade | Oppenheimer | Perform → Outperform |
| Sep-24-21 | Initiated | RBC Capital Mkts | Outperform |
View All
Avalo Therapeutics Inc Stock (AVTX) Latest News
What drives Avalo Therapeutics Inc. stock priceHigh-yield investments - PrintWeekIndia
Avalo Therapeutics Inc. Stock Analysis and ForecastAccelerated capital growth - PrintWeekIndia
When is the best time to buy Avalo Therapeutics Inc. stockExponentially increasing returns - jammulinksnews.com
What analysts say about Avalo Therapeutics Inc. stockUnmatched market gains - Autocar Professional
Is Avalo Therapeutics Inc. a good long term investmentUnmatched market performance - jammulinksnews.com
Stifel reiterates Buy rating on Avalo Therapeutics stock, maintains $36 target By Investing.com - Investing.com South Africa
Stifel reiterates Buy rating on Avalo Therapeutics stock, maintains $36 target - Investing.com Australia
Avalo Therapeutics Soars 10.66% on Bullish Sentiment - AInvest
Avalo Therapeutics (AVTX) Soars 10.42% on Analyst Upgrade - AInvest
What makes Avalo Therapeutics Inc. stock attractive to long term investorsBalanced Risk Reward Portfolio - Newser
Does Avalo Therapeutics Inc. stock pay reliable dividendsReal Time Alert Service - Newser
What institutions are buying Avalo Therapeutics Inc. stock nowGrowth Optimized Stock Radar - beatles.ru
What makes Avalo Therapeutics Inc. stock price move sharplyBreakout Confirmation Tool - Newser
Why Avalo Therapeutics Inc. stock attracts strong analyst attentionIntraday Trade Ideas - Newser
How Avalo Therapeutics Inc. stock performs during market volatilityVolume Spike Monitors - Newser
(AVTX) Investment Analysis and Advice - news.stocktradersdaily.com
Avalo Adds Dr. Rita Jain to Board as LOTUS Trial Advances - MSN
Avalo Therapeutics, Inc. (NASDAQ:AVTX) Receives Consensus Recommendation of “Buy” from Brokerages - Defense World
How To Trade (AVTX) - news.stocktradersdaily.com
15 Best Growth Stocks to Invest in for the Next 5 Years - Insider Monkey
Avalo Therapeutics to Participate in Upcoming Investor Conferences - GlobeNewswire
Avalo Therapeutics Highlights Potential of AVTX-009 in HS - TipRanks
(AVTX) Long Term Investment Analysis - news.stocktradersdaily.com
Avalo Therapeutics appoints Dr. Rita Jain to board of directors By Investing.com - Investing.com Nigeria
Avalo Therapeutics (AVTX) Welcomes New Board Member | AVTX Stock News - GuruFocus
Avalo Therapeutics Announces Appointment of Rita Jain, M.D. to Board of Directors - GlobeNewswire
Avalo Therapeutics Announces Appointment of Rita Jain, M.D. to B - GuruFocus
Avalo Therapeutics appoints Dr. Rita Jain to board of directors - Investing.com
Avalo Therapeutics, Inc. (NASDAQ:AVTX) Short Interest Down 45.8% in May - Defense World
Avalo Therapeutics Inc Stock (AVTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.97%
0.22%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):